What is HC Wainwright’s Forecast for EBS Q3 Earnings?

Emergent Biosolutions Inc. (NYSE:EBS) – Equities researchers at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Emergent Biosolutions in a research note issued on Monday, August 10th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will post earnings of ($0.75) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Emergent Biosolutions’ Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($4.63) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at $0.23 EPS, Q3 2027 earnings at $0.22 EPS, Q4 2027 earnings at $0.35 EPS and FY2027 earnings at $0.28 EPS.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The company had revenue of $234.30 million during the quarter, compared to analyst estimates of $177.50 million.

Other equities analysts have also issued reports about the stock. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Emergent Biosolutions in a research report on Friday. Finally, Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Emergent Biosolutions presently has an average rating of “Hold” and an average target price of $10.00.

Emergent Biosolutions Stock Down 0.8%

Shares of NYSE:EBS opened at $4.43 on Wednesday. Emergent Biosolutions has a 12 month low of $4.36 and a 12 month high of $14.06. The company’s 50-day moving average price is $7.66 and its two-hundred day moving average price is $8.65. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. The firm has a market cap of $227.38 million, a P/E ratio of -1.25 and a beta of 2.35.

Institutional Investors Weigh In On Emergent Biosolutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Emergent Biosolutions during the second quarter worth about $39,525,000. Dimensional Fund Advisors LP boosted its stake in Emergent Biosolutions by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after acquiring an additional 504,553 shares during the last quarter. State Street Corp grew its holdings in Emergent Biosolutions by 10.2% during the fourth quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock valued at $33,327,000 after purchasing an additional 250,616 shares during the period. Millennium Management LLC grew its holdings in Emergent Biosolutions by 68.9% during the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Emergent Biosolutions by 17.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock valued at $20,010,000 after purchasing an additional 237,153 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Insiders Place Their Bets

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by corporate insiders.

Emergent Biosolutions News Summary

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a recovery to positive earnings in 2027, including $0.28 in full-year EPS and positive EPS in the second through fourth quarters. However, its price target was reduced to $10 from $12, still implying substantial upside from recent levels. HC Wainwright lowers Emergent BioSolutions price target
• Neutral Sentiment: HC Wainwright expects EBS to remain unprofitable in the near term, forecasting EPS of ($0.75) for Q3 2026, ($0.64) for Q4 2026 and ($4.63) for full-year 2026. The firm then forecasts a ($0.53) loss in Q1 2027, followed by improving profitability in later quarters. HC Wainwright forecast for Emergent BioSolutions
• Negative Sentiment: Emergent BioSolutions cut its 2026 revenue guidance to $645 million-$675 million, down from the previously reaffirmed $720 million-$760 million outlook. The sharp reduction raises concerns about demand, execution and near-term cash flow. Emergent BioSolutions guidance cut and investigation notice
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations related to Emergent’s business disclosures. The legal uncertainty adds another risk for shareholders following the guidance reduction. Levi and Korsinsky investigation notice

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.